Endoprotease 40 (E40) | First ever preventive treatment for celiac disease and gluten sensitivity

Summary
E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.

Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD). The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.

E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.

E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten
Results, demos, etc. Show all and search (0)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/190138713
Start date: 01-06-2023
End date: 31-05-2025
Total budget - Public funding: 4 243 109,69 Euro - 2 499 999,00 Euro
Cordis data

Original description

E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.

Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD). The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.

E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.

E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten

Status

SIGNED

Call topic

HORIZON-EIC-2023-ACCELERATOROPEN-01

Update Date

12-03-2024
Images
No images available.
Geographical location(s)